SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-276007
Filing Date
2023-11-13
Accepted
2023-11-13 16:06:07
Documents
15
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d85328d8k.htm   iXBRL 8-K 26011
2 EX-99.1 d85328dex991.htm EX-99.1 73887
6 GRAPHIC g85328g1113015923942.jpg GRAPHIC 2372
7 GRAPHIC g85328g1113020243707.jpg GRAPHIC 2223
  Complete submission text file 0001193125-23-276007.txt   243387

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20231113.xsd EX-101.SCH 2890
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20231113_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20231113_pre.xml EX-101.PRE 11288
9 EXTRACTED XBRL INSTANCE DOCUMENT d85328d8k_htm.xml XML 3396
Mailing Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BLDG. 17, SUITE 401 WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 231398624
SIC: 8071 Services-Medical Laboratories